Lv2
167 积分 2021-11-16 加入
Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial
6天前
已完结
Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial
6天前
已完结
Complete Regression of Hepatoblastoma after Interleukin-15– and Interleukin-21–Coexpressing CAR T-Cell Therapy
13天前
已完结
Soluble expression of recombinant human interleukin-2 in Escherichia coli and its facile production
26天前
已完结
Daraxonrasib for Previously Treated RAS-Mutant Non–Small-Cell Lung Cancer
1个月前
已完结
Daraxonrasib for Previously Treated RAS-Mutant Non–Small-Cell Lung Cancer
1个月前
已完结
SKYSCRAPER-03: A Phase III Study of Tiragolumab Plus Atezolizumab Versus Durvalumab in Locally Advanced, Unresectable, Stage III NSCLC After Platinum-Based Concurrent Chemoradiation
1个月前
已完结
Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results
2个月前
已完结
Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial
2个月前
已完结
Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial
2个月前
已完结
皖公网安备34019202002308
